Annexin A1 Mimetic Peptide Ac2-26 Modulates the Function of Murine Colonic and Human Mast Cells

Author(s)

Oliveira, Marcia Pereira ^[1] ; Prates, Janesly ^[2] ; Gimenes, Alexandre Dantas ^[3] ; Correa, Silvia Graciela ^[4] ; Oliani, Sonia Maria ^{[2, 5, 6]}

Affiliation

^[1] Fiocruz MS, Lab Interdisciplinary Med Res, Oswaldo Cruz Inst, Rio De Janeiro - Brazil

^[2] Sao Paulo State Univ Unesp, Inst Biosci, Dept Biol, Sao Jose Do Rio Preto - Brazil

^[3] Faceres Sch Med, Dept Funct Morphol, Sao Jose Do Rio Preto - Brazil

^[4] Univ Natl Cordoba UNC, Dept Bioquim Chn, Ctr Invest Bioquim Clin & Inmunol MCI CONICET, Fac Ciencias Quim, Cordoba - Argentina

^[5] CEPAM Unilago, Adv Res Ctr Med, Sao Jose Do Rio Preto - Brazil

^[6] Univ Fed Sao Paulo, Escola Paulista Med Unifesp EPM, Post Grad Program Struct & Funct Biol, Sao Paulo - Brazil

• Document type: Journal article
• Source: FRONTIERS IN IMMUNOLOGY; v. 12, SEP 7 2021.
• Web of Science Citations: 0

Abstract

Mast cells (MCs) are main effector cells in allergic inflammation and after activation, they release stored (histamine, heparin, proteases) and newly synthesized (lipid mediators and cytokines) substances. In the gastrointestinal tract the largest MC population is located in the lamina propria and submucosa whereas several signals such as the cytokine IL-4, seem to increase the granule content and to stimulate a remarkable expansion of intestinal MCs. The broad range of MC-derived bioactive molecules may explain their involvement in many different allergic disorders of the gastrointestinal tract. Annexin A1 (AnxA1) is a 37 KDa glucocorticoid induced monomeric protein selectively distributed in certain tissues. Its activity can be reproduced by mimetic peptides of the N-terminal portion, such as Ac2-26, that share the same receptor FPR-L1. Although previous reports demonstrated that AnxA1 inhibits MC degranulation in murine models, the effects of exogenous peptide Ac2-26 on intestinal MCs or the biological functions of the Ac2-26/FPR2 system in human MCs have been poorly studied. To determine the effects of Ac2-26 on the function of MCs toward the possibility of AnxA1-based therapeutics, we treated WT and IL-4 knockout mice with peptide Ac2-26, and we examined the spontaneous and compound 48/80 stimulated colonic MC degranulation and cytokine production. Moreover, in vitro, using human mast cell line HMC-1 we demonstrated that exogenous AnxA1 peptide is capable of interfering with the HMC-1 degranulation in a direct pathway through formyl peptide receptors (FPRs). We envisage that our results can provide therapeutic strategies to reduce the release of MC mediators in inflammatory allergic processes.</p> (AU)

• FAPESP's process: 19/19949-7 - Evaluation of annexin A1 protein immunomodulatory activity in cutaneous and placental lesions resulting from Diabetes Mellitus
• Grantee: Sonia Maria Oliani
• Support Opportunities: Regular Research Grants